WA
REGN icon

Waverly Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Waverly Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.56M Buy
5,895
+3,250
+123% +$2.49M 0.03% 429
2025
Q4 		$2.04M Buy
2,645
+776
+42% +$527K 0.02% 595
2025
Q3 		$1.05M Buy
1,869
+521
+39% +$295K 0.01% 626
2025
Q2 		$708K Sell
1,348
-78
-5% -$43.5K 0.01% 707
2025
Q1 		$904K Buy
1,426
+146
+11% +$100K 0.01% 628
2024
Q4 		$912K Buy
1,280
+239
+23% +$201K 0.01% 539
2024
Q3 		$1.09M Sell
1,041
-5
-0.5% -$5.56K 0.02% 431
2024
Q2 		$1.1M Buy
1,046
+8
+0.8% +$7.75K 0.02% 423
2024
Q1 		$999K Buy
1,038
+268
+35% +$255K 0.02% 368
2023
Q4 		$676K Sell
770
-12
-2% -$9.88K 0.03% 260
2023
Q3 		$644K Sell
782
-54
-6% -$42.4K 0.03% 235
2023
Q2 		$601K Buy
+836
New +$645K 0.03% 226
2017
Q3 		– Sell
-431
Closed -$212K – 236
2017
Q2 		$212K Buy
+431
New +$189K 0.05% 205
2014
Q4 		– Sell
-30
Closed -$11K – 614
2014
Q3 		$11K Hold
30
– – 0.01% 460
2014
Q2 		$8K Buy
30
+2
+7% +$593 ﹤0.01% 496
2014
Q1 		$8K Buy
+28
New +$8.63K ﹤0.01% 472

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Waverly Advisors's REGN Position: Q1 2026 in Review

Waverly Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 123% in Q1 2026, buying an estimated $2.49M and bringing the position to 5,895 shares worth $4.56M. The position accounts for 0.03% of the portfolio, ranked #429.

Waverly Advisors first reported a position in REGN in Q1 2014 and has held it in 16 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Waverly Advisors held 5,895 shares of Regeneron Pharmaceuticals worth $4.56M as of Q1 2026.
  • Waverly Advisors bought 3,250 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.49M.
  • Regeneron Pharmaceuticals made up 0.03% of Waverly Advisors's portfolio in Q1 2026, its #429 holding.
  • Waverly Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 16 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.